Axsome Therapeutics (AXSM) Common Equity (2015 - 2026)

Axsome Therapeutics has reported Common Equity for 12 years, with the latest figure at $54.6 million in Q1 2026.

• Quarterly Common Equity rose 2.6% year-over-year to $54.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.6 million (up 2.6% YoY) and the FY2025 annual result came in at $88.3 million, up 54.86% from the prior year.
• Common Equity slipped to $54.6 million in Q1 2026 per AXSM's latest filing, from $88.3 million in the prior quarter.
• Over five years, Common Equity peaked at $278.8 million in Q2 2023 and troughed at $14.7 million in Q1 2022.
• A 5-year average of $111.0 million and a median of $92.9 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity sank 84.74% in 2022, then soared 1734.36% in 2023.
• Over 5 years, Common Equity stood at $109.6 million in 2022, then surged by 74.32% to $191.0 million in 2023, then plunged by 70.15% to $57.0 million in 2024, then surged by 54.86% to $88.3 million in 2025, then tumbled by 38.18% to $54.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $54.6 million, $88.3 million, and $73.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.